logo
Plus   Neg
Share
Email

AstraZeneca: European Commission Approves Qtrilmet For Type-2 Diabetes

AstraZeneca (AZN.L,AZN) reported that the European Commission has approved Qtrilmet modified-release tablets to improve glycaemic control in adults with type-2 diabetes. The EC has approved Qtrilmet to improve glycaemic control in adults with type-2 diabetes when metformin with or without sulphonylurea and either Onglyza or Forxiga does not provide adequate glycaemic control, or when type-2 diabetes patients are already being treated with metformin, Onglyza and Forxiga.

Qtrilmet was approved in the US in May 2019 under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT